Genenta Science S.p.A.

Develops cell & gene therapies using engineered stem cells to treat solid tumors.

GNTA | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: OLGETTINA, NO. 58, 20132 MILAN
Website:: https://www.genenta.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genenta Science S.p.A. is a clinical-stage immuno-oncology company developing proprietary cell and gene therapies for the treatment of solid tumors. The company's technology is centered on engineering a patient's own hematopoietic stem cells using a lentiviral vector to combat cancer. Its lead candidate, Temferon, is designed to make tumors visible to the immune system by reprogramming the tumor microenvironment and breaking immune tolerance. Genenta has completed a Phase 1 clinical trial in Glioblastoma Multiforme and has initiated a Phase 1/2a study in metastatic Renal Cell Carcinoma. The treatments are designed as one-time monotherapies that also have the potential to be used in combination to enhance the efficacy of other therapeutics, such as immune checkpoint inhibitors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Genenta Science S.p.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genenta Science S.p.A.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Genenta Science S.p.A. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Biovica International B Develops blood tests to monitor the efficacy of solid tumor cancer therapies.	Sweden	BIOVIC
BIOVIE INC. Develops drug therapies for Alzheimer's, Parkinson's, and advanced liver diseases by targeting inflammation.	United States of America	BIVI
BioXcel Therapeutics, Inc. AI-driven biopharma developing treatments for neuroscience and immuno-oncology.	United States of America	BTAI
Black Diamond Therapeutics, Inc. Develops precision oncology drugs targeting mutation families in lung and brain cancers.	United States of America	BDTX
BL Pharmtech Corp. Manufactures and distributes health foods, supplements, and cosmetics with bio-pharmaceutical R&D.	South Korea	065170
BOIRON Global manufacturer of homeopathic medicines for pain relief and flu-like symptoms, sold worldwide.	France	BOI
Bon Natural Life Ltd Bio-manufactures natural plant ingredients for fragrances, supplements, and immunity solutions.	United States of America	BON
Bosnalijek d.d. Sarajevo Global manufacturer of drugs for digestive, metabolic, and cardiovascular health.	Bosnia and Herzegovina	BSNL
Boundless Bio, Inc. Developing ecDNA-directed therapies for intractable oncogene amplified cancers.	United States of America	BOLD
BridgeBio Oncology Therapeutics, Inc. Clinical-stage biopharma creating small molecule drugs for RAS-dependent cancers.	United States of America	BBOT